Clinical Trials | A Phase 3 Study of Fixed Dose Combinations of REGN3767 and REGN2810 Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have unresectable or metastatic melanoma. The study is researching an experimental drug called REGN3767, combined with another medication called REGN2810. The aim of the study is to see how safe and effective the combination of REGN3767 and REGN2810 is in treating melanoma, in comparison with the combination of two medications, relatlimab and nivolumab, commercialized under the brand name Opdualag™. Opdualag is currently approved for the treatment of melanoma that has spread beyond the lymph nodes or cannot be removed with surgery in adults and children 12 years of age or older. This study involves two combination drugs. You may receive either the combination of REGN3767 + REGN2810 or the combination of relatlimab + nivolumab. You will have an equal chance of receiving either of these two combination drugs. You will receive the study drugs every 3 or 4 weeks depending on which combination you are receiving. You will receive these drugs via an IV infusion into your arm. You will be in this study as long as you are receiving study drug and deriving benefit. After you stop receiving study treatment, the study team will follow up with you approximately every 3 months for 5 years. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. Additional information can be found here: https://clinicaltrials.gov/study/NCT06246916?term=NCT06246916 [email protected]